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ABSTRACT

Aberrant glycosylation takes place during the onset of cancer and throughout the
progression of the disease allowing certain glycans to serve as biomarkers1. Boronic acid
functionalized synthetic lectins (SLs) have been shown to bind selectively and crossreactively to certain glycoproteins through covalent yet reversible interactions between
the boronic acids and 1,2- or 1,3-diols found on saccharides2. This project focuses on 1)
data acquisition optimization of an existing SL array; 2) the identification, isolation, and
characterization of new SLs that interact with proteins and glycoproteins targeting the
prostate and prostate cancer; and 3) the utilization of new SLs in cross-reactive sensor
arrays to distinguish between prostate cells with differing metastatic potential. This
differentiation is based on the ability of the SLs to detect the subtle glycan changes in
diseased cells. The results presented in this dissertation highlight the immense potential
of SL arrays as tools in cancer diagnostics.
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CHAPTER 1:
INTRODUCTION AND BACKGROUND
1.0 ABSTRACT
Cancer, the uncontrolled growth of abnormal cells in the body, is one of the
leading causes of death not only in the United States but also worldwide. Cancer
diagnostics that can detect the disease in early stages have become a necessary means of
increasing a patient’s survival rate. Changes in glycosylation take place during the onset
of cancer and throughout the progression of the disease, which allows these glycans to
serve as biomarkers. This chapter will describe how boronic acid functionalized synthetic
lectins (SLs) have been developed as glycan sensors and how cross-reactive sensor arrays
can be a useful tool in designing a novel cancer diagnostic.
1.1 CANCER STATISTICS
According to the National Cancer Institute, it is estimated that there will be
1,685,210 new cases of cancer and 595,690 people will die from the disease in 2016. In
2013, approximately 14,140,254 people were living with cancer of any site in the United
States with the most common types of cancer being breast, lung and bronchus, prostate,
colon and rectum, and bladder cancer3.
1.2 CANCER DETECTION AND DIAGNOSIS
Early detection and treatment of cancer has shown to increase survival rates in
cancer patients and therefore makes the development of diagnostic tools imperative4.
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Even though there are ways of diagnosing cancer, many of the procedures are associated
with disadvantages.
One example of a “gold standard” cancer diagnostic is a colonoscopy, which is a
procedure that uses a colonoscope to examine the colon for abnormal growths. While it
has is the best way to visualize tumor growth, the test is expensive and invasive. Some
studies have shown that the efficacy of the procedure depends where the cancer is located
within the colon5-6. Colonoscopies can also cause potential health complications such as
lacerations, bleeding, and infection in the colon7.
Most diagnostics are also associated with false positives and false negatives.
False positives lead a patient to believe that they have cancer when they do not. The
procedures that follow a primary diagnosis cause the patient emotional stress and more
financial burden. For example, an exam that was previously used to diagnose prostate
cancer, the prostate specific antigen (PSA) test, has a 75% false positive test result rate,
meaning that only 25% of the men that undergo biopsies actually have cancer8. False
negatives lead a patient to believe that they do not have cancer when they really do,
preventing the patient from seeking medical attention sooner, which can lead to a more
advanced cancer before treatment. Due to its inability to diagnose prostate cancer
effectively, the PSA test is now being used as a means to monitor cancer progression in
patients that have been diagnosed through systematic prostate biopsy under ultrasound
guidance9.
Not only are cancer diagnostics associated with high false positive and false
negative rates, most are also ineffective in early stages of cancer, when the disease is
most treatable. Even though elevated levels of carcinoembryonic antigen (CEA) are
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known to be associated with colon cancer, the CEA test is only 4% and 25% effective in
the first and second stages of cancer, respectively10. This test was also discontinued as a
screening test and utilized as a cancer progression monitor similar to the PSA test11.
Relatively new tests such as the fecal immunochemical test (FIT) and the guaiac-based
fecal occult blood test (gFOBT) have emerged as screening tools. These tests detect
blood in stool that is present due to colon cancer. While these tests are less invasive than
a colonoscopy, they also cannot detect new growth, which leads to false negatives12-14.
Clearly there is a dire need for new cancer screening tests. An ideal test would
quick, inexpensive, and have a low amount of risk associated with it. The test would also
need to have low false positive and false negative rates.
1.3 ABERRANT GLYOSYLATION
Proteins that have carbohydrate chains (glycans) attached to them via co- or posttranslational glycosylation are glycoproteins. Over 70% of proteins are glycosylated15.
Glycans are linked to proteins in two different ways: N-linked, where the glycan is
attached through the side chain of an asparagine residue, or O-linked, where the glycan is
attached through a serine or threonine residue16. During the onset of cancer, aberrant
glycosylation takes place in which glycan structures are over, under, or neo-expressed
(Figure 1.1). The expression of glycans not only changes on inter-membrane
glycoproteins but also on glycoproteins that are secreted. These changes continue
throughout the progression of the disease and therefore create specific biomarkers for
non-cancerous and cancerous cells, which could be used to diagnose cancer17.
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Figure 1.1 Aberrant Glycosylation. After the onset of cancer, normal glycan structures
(the green chains on the left) are altered. The glycans can be over, under, or newly
expressed, represented in the red and yellow chains.
1.4 CANCER ASSOCIATED GLYCANS
The glycosylation changes that take place are due to changes in glycotransferase
levels. These glycotransferase changes alter the composition of the glycan chains that are
attached to proteins. Some common cancer associated glycans are found in Figure 1.2.

Figure 1.2 Common cancer associated glycan structures.
4

Many glycan structures have been found to be associated with certain cancer
types (Table 1.1)18. It is important to note that not one type of cancer listed has the same
combination of cancer-associated glycans, which creates a specific pattern for each
cancer type. It is also important to add that some cancers have very similar patterns. For
example breast and colon cancer have the same pattern except for the overexpression of
polysialic acid in breast cancer. It is also interesting that breast and prostate cancer have
very different patterns, differing by three cancer-associated glycans. The ability to detect
the different patterns would provide a potential cancer diagnostic.
Table 1.1 Common overexpression patterns of cancer associated glycans on malignant
tissues18.

While many glycoproteins have been used to detect cancer, such as PSA and
CEA, these diagnostics rely on detecting the amount of the glycoproteins themselves and
not the changes in the glycan structures of the glycoproteins. These detection methods are
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associated with high false positive and high false negative rates, therefore many of these
diagnostics have become methods to monitor the disease after the disease has been
confirmed10.
1.5 DETECTION OF GLYCANS
An ideal sensor that could detect the glycans and the changes occurring would
have high specificity towards its target, stability, and low costs. Natural lectins are
carbohydrate-binding proteins that have a high affinity to sugars and high specificity.
These proteins could act as sensors in a cancer diagnostic but are costly and
experimentally challenging19.
1.6 BORONIC ACID-DIOL INTERACTION
In order to circumvent the previously stated disadvantages of natural lectins,
boronic acids have been utilized in several different glycan sensors because boronic acids
are known to form covalent yet reversible boronate esters with 1,2- and 1,3- diols, which
are found on glycans, to produce cyclic boronate esters. The interaction between boronic
acids and diols commonly found on glycans can be found in Figure 1.3.

Figure 1.3 Interaction between boronic acids and 1,2- or 1,3- cis diols.
When using boronic acids in glycan sensors, it is important to understand what
influences the boronic acid-diol interaction. The equilibrium between phenylboronic acid
and a diol can be found in Figure 1.4.
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Figure 1.4 The equilibrium between phenylboronic acid and a diol.
The equilibrium is very dependent on pH. At higher pH, boronic acid becomes a boronate
anion (in Figure 1.4, 1 à 2 or 3 à 4). The boronate anion has a tetrahedral geometry
making the bond angles around the boron similar to the bond angle of the cycle boronate
ester. This limits the use of boronic acid functionalized sensors at physiological pH20.
In order to use boronic acids on sensors at physiological pH, the Anslyn group
investigated intramolecular boron-nitrogen interactions. They found that in neutral
aqueous solutions, the incorporation of an ortho aminomethyl group to phenylboronic
acid allowed boronic ester formation with diols21. The aminomethyl group interacts with
the empty p orbital on the boron transforming the geometry into the favored tetrahedral
conformation. The Anslyn group proposes two reasons for this boronate ester formation
increase. First, the solvolysis of the boron is promoted because the nitrogen can act as a
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Bronsted-Lowry base. Second, there is a weak dative bond between the nitrogen and the
boron. Both of these explanations facilitate the boronate ester formation at physiological
pH (Figure 1.521).

Figure 1.5 An aminomethyl group ortho to phenylboronic acid facilitates binding with
diols at physiological pH.
1.7 BORONIC ACID FUNCTIONALIZED SENSORS
Many boronic acid functionalized sensors have been developed for different types
of saccharide sensing with particular interest in D-glucose. As previously stated, sensing
sugars can be valuable when trying to diagnose cancer and other diseases. The specific
recognition of boronic acid for cis-diols provides selectivity in sensing. The structures of
many different boronic acid functionalized sensors used in fluorescent, colorimetric, and
electrochemical methods are in Figure 1.6.
Yoon and Czarnik used the first fluorescent probe using anthrylboronic acid
(Figure 1.6a)22. When the boronic acid was bound to a sugar, the anionic boronate ester
was formed and fluorescence intensity decreased by 40%. This decrease in fluorescence
intensity was not extensively studied but it was thought that the boronate ester formation
quenched the anthracene fluorescence. This sensor encouraged other researchers to work
in this field of chemistry.
Intramolecular charge transfer (ICT) was also applied to develop fluorescent
sensors. Substituted stilbenes containing boronic acid were synthesized by the Lakowicz
group as sugar sensors (Figure 1.6b)23. The boron on the boronic acid acted as a Lewis
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acid and the R group was an electron-donating group such as an amine or methoxy group.
Therefore, electrons were transferred from an electron-donating group to the electronaccepting boron through a spacer fluorophore. When the boronic acid converted to the
boronate ester in the addition of a sugar at high pH, the boron does not accept electrons
anymore and this loss of charge transfer disrupts the fluorescent properties.

Figure 1.6 Structures of boronic acid functionalized sensors used for sugar sensing. (a)
first fluorescent probe, (b) Intramolecular charge transfer (ICT) sensors, (c-e)
Photoinduced electron transfer (PET) sensors, (f-g) electrochemical sensors.
Shinkai’s group was the first to design PET sensors for sugars (Figure 1.6c)24.
They used N-methyl-o-(aminomethyl)phenylboronic acid as the recognition motif and
connected to a fluorophore anthracene through a methylene spacer. The amine in close
proximity to the boronic acid allows for the interaction between the boronic acid and
diols at neutral pH. Also, the amine-boron interaction dictates the molecule’s ability to
fluoresce. Without the sugar binding, the sensor is in an “off” state due to the nitrogen’s
lone pair. The lone pair quenches the fluorescence of anthracene. When binding the
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sugar, the nitrogen coordinates with the boron and prevents fluorescence quenching by
PET. These sensors exhibited some selectivity for sugars with it being the most selective
for D-fructose. Unfortunately, the selectivity was altered when the amounts of boronic
acid or the geometry around the boron was changed. Another example of an anthracenebased diboronic acid system is shown in Figure 1.6d25. This sensor had high selectivity
for D-glucose over other sugars.
Wang’s group developed a series of diboronic acid sensors using a similar
strategy to the PET mechanism. This series had different linkers between two anthracene
fluorophores (Figure 1.6e)26-27. The investigated these sensors’ ability to selectively bind
to cancer associated glycans. Wang’s group found that the compounds with the parabenzene linker showed moderate selectivity for Sialyl Lewis X.
Other sensors that were developed were electrochemical sensors. James’s group28
attached electro-active ferrocene to monoboronic acid (Figure 1.6f) or diboronic acid
(Figure 1.6g). Overall, the diboronic acid sensor was more selective for D-glucose and Dgalactose compared to the monobonoric acid sensor.
As discussed earlier, the recognition of more complex saccharides can play a
valuable role in the detection of many different diseases. This is due to the cis-diols that
are found on glycans and glycoproteins and their ability to interact with boronic acids.
The differences in the sugar structures in glycans and glycoproteins in cancerous states
create the need for sensors and therefore, boronic acids have been incorporated into many
biosensors for their application in cancer diagnostics.
Boronolectins are the biosensors that have been developed in the cancer
diagnostic area. The selectivity of these sensors has been greatly improved over the years.
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One important feature of the sensors was the biocompatibility. In order to optimize these
sensors, they needed to have good water solubility, low toxicity, and more stability than
the other sugar sensors. Most of the fluorescent boronic acid sensors had poor water
solubility and therefore needed organic co-solvents for sugar binding studies. Wang’s
group developed different sensors that contained quinolone and naphthalene. These
structures improved water solubility and stability. When binding to glycans, the
fluorescence of these sensors changed. The changes were specific to each glycan29-34.
While all of these sensors were promising in glycan sensing, they still had
limitations. In order to overcome these limitations, Hall used a library technique to find
sensors that targeted the TF antigen, which is a cancer-associated glycan. He used a
peptide backbone due to its biocompatible properties. The peptide backbone also had the
potential to have secondary interactions with the glycans, which could enhance binding
affinity and selectivity. Hall found that peptides functionalized with boroxoles or boronic
acids had more selectivity for the TF antigen compared to peptides without those
groups35.
1.8 BORONIC ACID FUNCTIONALIZED SYNTHETIC LECTINS
Previously, an array of boronic acid functionalized synthetic lectins (SLs) was
isolated from a fixed-position library screening against purified glycoproteins PSM and
OVA. The general sequence of the SLs was Ac-R-X-D*-X-X-X-D*-X-B-B-R-M-resin
where X denotes a random AA position, D* denotes Dab functionalized with PBA, and B
denotes beta-alanine, which acts as a spacer between the resin and the peptide sequence.
Four SLs were identified and sequenced using MS/MS (Table 1.2).
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Table 1.2 Sequences of SLs screened against purified glycoproteins PSM and OVA.
SL Hit

Sequence

SL1

Ac-R-G-D*-V-T-F-D*-R-B-B-R-M-resin

SL3

Ac-R-S-D*-V-T-T-D*-R-B-B-R-M-resin

SL4

Ac-R-R-D*-T-Q-T-D*-Q-B-B-R-M-resin

SL5

Ac-R-A-D*-T-R-V-D*-V-B-B-R-M-resin

After the SLs were sequenced and resynthesized, the SLs were incubated with the
purified glycoproteins to assess the selectivity/cross-reactivity of each SL. Unlike a
“lock-and-key” approach, the SLs were not highly selective for one glycoprotein.
This is not a problem when using the SLs in an array because the SLs only need
to have different affinities for a certain analyte, which produces a unique fingerprint
pattern (Figure 1.7). Cross-reactive sensor arrays are similar to the mammalian sense of
taste. It is not how one taste bud reacts with a type of food but how all of the taste buds
react to form a pattern that the brain stores as a certain taste.

Figure 1.7 Cartoon of cross-reactive sensors/receptors arranged into a sensor array. In this
figure, four of the receptors bind to a single analyte differently. The combined signals
from the receptors create a unique pattern for the analyte.
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Through linear discriminant analysis, previous lab members have used the four
SL array to distinguish between seven colon cancer cell lines with 92% classification
accuracy (Figure 1.8).

Figure 1.8 SL cross-reactive sensor array discriminating seven colon cell types. A) The
two-dimensional (2-D) LDA score plot of the SL array discriminating seven colon cell
types. The green curved lines highlight the separation of healthy, cancerous/nonmetastatic, and cancerous/metastatic cell types. B) Leave-one-out cross validation
classification matrix for the discrimination of the seven colon cell types. Overall
classification accuracy was 92% with a classification error of 8%. The expected chance
accuracy of the SL array was 14.3%.
While being able to distinguish cell lines is important, in thinking about a
clinically relevant diagnostic there are two important initial questions: Does the patient
have cancer? Has the cancer metastasized? With this in mind, the analysis was done to
see if the array can differentiate based on metastatic potential (non-cancerous, cancerous
low metastatic, and cancerous high metastatic. The array was also able to differentiate the
seven cell lines by metastatic potential with 97% accuracy (Figure 1.9)2.
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Figure 1.9 Discrimination of seven colon cell types by metastatic potential. A) 2-D LDA
score plot of the SL cross-reactive array discriminating the seven colon cell types healthy,
cancerous/non-metastatic, and cancerous/metastatic. B) 2-D LDA score plot of the SL
cross-reactive array ungrouping the cancerous/non-metastatic cell types: HCT116, CT26, and HT-29. C) 2-D LDA score plot of the SL cross-reactive array ungrouping the
cancerous/metastatic cell types: CT-26-F1, CT-26-FL3, and LoVo.
1.9 THE NEED FOR NEW SLs
While the previous SLs show promise for a colon cancer diagnostic, there is a
need for new screening methods that utilize proteins and glycoproteins that come from
human sources. The SLs in the previous array were screened against purified
glycoproteins that were isolated from animal sources. Also, the array’s ability to
discriminate other types of cancer had not been investigated.
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CHAPTER 2:
LIBRARY SCREENING
2.1 LIBRARY SYNTHESIS
Previous work was done to optimize the SL library screening against purified
glycoproteins. The general peptide sequence that was found to have the most diversity
with relatively easy sequencing ability when using Matrix Assisted Laser
Desorption/Ionization (MALDI) was Ac-R-X-D*-X-X-X-D*-X-B-B-R-M-Resin, where
the boronic acid moieties are fixed; D* denotes phenylboronic acid (PBA) functionalized
Diaminobutyric acid (Dab), B represents β-alanine, and X is a randomized amino acid.
Dab is used in place of Lys because of its shorter side chain, which is thought to reduce
background binding and increase interactions between the glycoproteins and the peptide
backbone. O-aminomethyl PBA is incorporated because of its ability to bind to diols
under

physiological

conditions.

To

create

the

peptide

chain,

standard

Fluorenylmethyloxycarbonyl (Fmoc) protocols were used with O-BenzotriazoleN,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) activation. The MRBB
sequence was coupled to all beads. Methionine is the first AA because it provides a way
to cleave the peptide from the resin using cyanogen bromide. Arginine was incorporated
because it aids in MS/MS sequencing by integrating a positive charge and the β-alanine
acts as spacers, which increases the distance between the remaining sequence and resin.
PBA moieties were fixed to also aid in MS/MS sequencing. The randomized amino acids
were coupled in a split-and-pool method.
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Figure 2.1 Split and pool combinatorial methods used to generate SL peptide libraries.
For randomized AA positions in the SL library, the resin is separated equally into 11
tubes and a different activated AA is added to each tube. Once the AA is coupled, the
resin from all the tubes is combined to deprotect the N-terminus Fmoc protecting group.
Of the 20 AAs, methionine, cysteine, isoleucine, proline, histidine, glutamic acid,
aspartic acid, lysine, and tryptophan were excluded from the randomized positions.
Methionine is used as the first amino acid in all of the SL sequences to enable peptide
cleavage from the bead when treated with cyanogen bromide so methionine and cysteine
are not used in the randomized amino acid positions to eliminate the chance of cutting the
peptide sequence into pieces. Isoleucine is omitted to eliminate the chance of mistaking
the amino acid for leucine when sequencing unknown SLs. Proline is excluded to avoid
having SLs with turns. Histidine, glutamic acid, aspartic acid, and lysine were not used
due to charged side chains. Tryptophan is not included because of its big and bulky side
chain. The N-terminus arginine has the same benefits as the first arginine and the acetyl
group is a cap that prevents reactions from taking place with the end of the sequence.
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The PBA functional group was attached through a reductive amination reaction
once the protecting group on the commercially available Dab was removed. The peptide
was then treated with TFA to remove the remaining side-chain protecting groups.
2.2 MS/MS SEQUENCING
After the library was incubated with a fluorescently labeled analyte and hits were
manually isolated, the SL was prepared for MS/MS sequencing. The analyte were washed
away from the SL and the PBAs were removed as well. The SL peptide was then cleaved
from the Tentagel resin.
Previous lab members used MALDI to sequence SLs. However, due to
instrumentation complications and lab conditions, the hits isolated from screenings
against the prostate analytes could not be sequenced. In attempts to still recover the
sequence, another MS/MS technique, Orbitrap, was used. While the orbitrap has the
ability to detect the small amount of peptide from one bead, it was still unable to
sequence the cleave peptide from the hits.
2.3 EDMAN DEGREDATION
In order to sequence hits from library screenings against prostate analytes, an
alternative method of peptide sequencing, Edman Degradation, was used. However, due
to the experimental procedures, a few modifications were made to the SL library.
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Figure 2.2 Mechanism for Edman Degradation. The N-terminus amino group reacts with
phenyl isothiocyanate under basic conditions. The resulting cyclic phenylthiocarbamoyl
derivative is then cleaved under strong acidic conditions to produce an
anilinothiazolinone derivative, which is selectively extracted with an organic solvent. The
derivative is then converted to phenylthiohydrantoin (PTH) under strong acidic
conditions.
In the first step of Edman Degradation, the N-terminus amine reacts with
phenylisothiocyanate to form a phenylthiocarbamyl-peptide derivative. If the N-terminus
is chemically modified with an acyl (Ac) group, the reaction cannot take place and
therefore sequencing cannot take place. In the original peptide synthesizing procedure,
the Ac protected the terminal amine from being functionalized with PBA. The synthetic
method was modified so that after the last arginine was coupled to the resin, the Fmoc
protecting group was not deprotected with 20% piperidine in DMF. This step was
removed and the rest of the steps continued in the same order. The ivDde-protecting
group on Dab was removed with 5% hydrazine in DMF and PBA was attached. The
Fmoc-protecting group was then deprotected with 20% piperidine in DMF and acid labile
groups were removed using the same methods stated above.
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After screening the new library and sequencing hits against the prostate
membrane extracted proteins and glycoproteins, the SLs were resynthesized using the
same protocol for Edman Degradation sequencing. Orbitrap MS/MS was used to verify
the peptide sequence of the resynthesized SL and the number of boronic acids attached to
the peptide.

Figure 2.3 Fmoc deprotection mechanism. Under basic conditions, the fluorenyl proton is
deprotected to which produces the deprotected amino group, dibenzofulvene, and carbon
dioxide.
The Fmoc deprotection mechanism is shown in Figure 2.3. Because the βhydrogen of the Fmoc group is so acidic, bases such as piperidine can drive the
deprotection of Fmoc. Hydrazine, which has a slightly higher pKb than piperidine, can
also act as a base and deprotect the Fmoc as well. Orbitrap MS/MS concluded that the
Fmoc group was deprotected by the 5% hydrazine in DMF solution that also deprotected
the ivDde-protecting group on Dab. This means that when the boronic acid coupling
occurred, 3 boronic acids were attached to the SL sequence; two located on the side
chains of the Dab AAs and one located on the terminal amine of the peptide backbone.
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Figure 2.4 Orbitrap LC chromatogram of SL11.

Figure 2.5 Orbitrap MS spectrum of SL11. The 1751 peak correlates with the total weight
of SL11 with 3 PBA groups.
2.4 SCREENING AGAINST MEMBRANE EXTRACTED GLYCOPROTEINS
Previous lab members identified SLs that interacted with glycoproteins by
screening the library against PSM, BSM, and OVA. These glycoproteins were chosen
because they were easily accessible and they contain unique glycan structures associated
with colon cancer such as sLex3,

36

. The hits from the screening were isolated and
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sequenced through MS/MS. When arranged in a cross-reactive sensor array, the 4 SLs
discriminated 7 colon cancer cell lines with 92% classification accuracy determined by 3
different cross-validation techniques: Jackknife, Boot-strap, and Training/test set.
Furthermore, when discriminating the 7 cell lines by metastatic potential, the array had
97% classification accuracy2.
When using the 4 SL cross-reactive sensor array to discriminate prostate cancer
cell lines, the classification accuracy decreased. In order to discover SLs that
discriminated prostate cancer cell lines with high classification accuracy and had
potential to be used in a prostate cancer diagnostic, a solution containing membrane
bound proteins and glycoproteins were used as a screening analyte. Figure 2.6 is a
general schematic for the screening procedure with membrane proteins and
glycoproteins.
Two different prostate cell lines RWPE-1 and PC3, not cancerous and cancerousmetastatic, respectively, were chosen as analytes. The membrane proteins and
glycoproteins were extracted using the membrane extraction kit that was used for the
colon cancer cell line discrimination. By using the proteins and glycoproteins from
prostate cell membranes, the hits isolated from the screening were more specific to
prostate related glycosylation and the aberrant changes that are present.
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Figure 2.6 Workflow for screening a SL library to identify hits. Prostate cells are cultured
and the membrane proteins and glycoproteins were extracted with Qiagen Plasma
Membrane Protein Kit. After the extraction, the sample was labeled with fluorescein and
then incubated with the SL library. The unbound fluorescent sample was washed away
and library resin that was fluorescent were identified and isolated for sequencing.
Three hits were found when screening against fluorescent prostate cell membrane
extracts. The first hit, SL10, was found when screening against F-PC3 (Figure 2.7). The
second hit, SL13, was found when screening against F-RWPE-1 (Figure 2.8). The third
hit, SL14, was found when screening against R-PC3 (Figure 2.9). For each hit, the SL
that was more fluorescent than the surrounding SLs was manually removed. The
fluorescent proteins and glycoproteins were removed from the SL by three alternating
acid/base washes (70% TFA in H2O and 0.1 M NaOH) and then the individual SLs was
sent to Tufts University Core Facility where the resin was sequencing by Edman
Degredation.
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Figure 2.7 SL10 hit located in the top left of the frame. This SL was screened against FPC3.

Figure 2.8 SL13 hit located in the top right of the frame. This SL was screened against FRWPE-1.

Figure 2.9 SL14 hit located in the top right of the frame. This SL was screed against RPC3.
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The sequences for SL10, SL13, and SL14 can be found in Table 2.1 (for all
Edman Degradation sequencing data, see Appendix A). Sequencing for B-B-R-M was
not performed because the first AA was manually coupled and the next three AAs were
coupled to the resin using a peptide synthesizer. When looking at the sequencing data,
many of the AA positions are clear but some are difficult to distinguish.
Table 2.1 SL10-14 sequences, selectivity and the analyte it was screened against.
SL

Sequence

Screened Against

Selectivity

SINGLE ANALYTE SCREEN
SL10

R-L-D*-A-R-S-D*-G-B-B-R-M

F PC3

SL13

R-T-D*-G-L-A-D*-V-B-B-R-M

F RWPE-1

SL14

R-Y-D*-R-A-S-D*-V-B-B-R-M

R PC3

DUAL ANALYTE SCREEN
SL11

R-L-D*-Y-L-T-D*-R-B-B-R-M

F RWPE-1/R PC3

PC3

SL12

R-L-D*-G-F-Y-D*-Q-B-B-R-M

F RWPE-1/R PC3

RWPE-1

In all of hits, the last AA, arginine, is not conclusive from the chromatogram but
the last AA is a fixed position in the library. The arginine was manually coupled to the
combined library at one time and the coupling was verified through a ninhydrin test. It is
also hard to distinguish the Dab positions when referring to the sequencing
chromatograms but it is similar to the last AA position. It is most important to look for
changes from cycle to cycle within the SL sequence. The absolute quantities of the AAs
in a single cycle is not as important due to the fact that different AAs have different
background levels. Appendix B contains all chromatograms from the protein sequencing
performed by Tufts University.
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2.5 DUAL DYE SCREENING
As stated above, the purpose of the library screenings against prostate membrane
extracts was to find SLs that interacted with relevant prostate proteins and glycoproteins.
In order to identify SLs that could bind differently to non-cancerous samples versus
cancerous samples, the prostate analytes that were used in the single screenings were
combined to create a dual dye library screening.

Figure 2.10 Dual Dye Screening Process. In order to select SLs that were selective, a dual
dye screening process was used. In this process, the membrane glycoproteins from two
different cell lines, one non-cancerous and the other cancerous-metastatic, were labeled
with fluorescent dyes of different colors. In this figure, the non-cancerous glycoproteins
were labeled with fluorescein and the cancerous-metastatic glycoproteins were labeled
with rhodamine.
The general schematic for the dual dye screening is in Figure 2.10. The
fluorescein-labeled non-cancerous RWPE-1 membrane proteins and glycoproteins were
combined with rhodamine-labeled PC3 membrane proteins and glycoproteins and
incubated with the library. After the resin was washed, the SLs that were fluorescent were
identified. The reverse dual dye screening was also performed where RWPE-1 was
labeled with rhodamine and PC3 was labeled with fluorescein. A bead that was more
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fluorescent in the green channel than any of the other beads in that channel but was not
more fluorescent than the other beads in the red channel (or vice versa) was selected.
Two hits were isolated from the dual dye screening. The sequences for both SLs
can be found in Table 2.1 and the sequencing data can be found in Appendix A. The first
hit from dual dye screening was SL11. The SL was isolated from the library screening
against F-RWPE-1 and R-PC3 combined. It was more fluorescent than the SLs
surrounding it in the red channel but it was not more fluorescent than the same beads in
the green channel (Figure 2.11). This means that SL11 bound more to PC3 membrane
extract that the other SLs but it did not bind more to RWPE-1 than the other SLs.

Figure 2.11 SL11 hit. This hit was found by dual dye screening with F-RWPE-1 and RPC3. The hit is located in the bottom middle part of the right frame.
The second hit from the dual dye screening was SL12. It was also isolated from
the library screening against F-RWPE-1 and R-PC3 but it was more fluorescent in the
green channel versus the red channel meaning that it interacted more with RWPE-1 than
PC3 (Figure 2.12).

26

Figure 2.12 SL12 hit. This hit was found by dual dye screening with F-RWPE-1 and RPC3. The hit is located in the middle part of the left frame.
2.6 RESYNTHESIZING SL10-14
After the sequences of SL10-14 were identified, the SLs were resynthesized to
confirm the structure of the overall SL. As stated previously, the new library synthesis
protocol did not remove the Fmoc protecting group with 20% piperidine in DMF before
deprotecting the ivDde protecting group on Dab. However, due to hydrazine’s ability to
act as a base like piperidine, hydrazine could remove the Fmoc protecting group and
therefore allow for a third PBA group to be present.
To verify the structure, the SLs were first resynthesized using the same protocol as
the new library. Once the peptide sequences had been coupled to resin, the ivDde groups
were deprotected and PBAs were attached. The Fmoc group was then deprotected and the
acid labile groups were removed. The SL was then cleaved from the bead using cyanogen
bromide overnight and analyzed by Orbitrap (Figure 2.4 and Figure 2.5). The masses
found for each SL showed that the SL had three PBA groups instead of two like the
previous SL1, 3, 4, and 5.
2.7 CONCLUSION
In this chapter, library synthesis and screening against prostate specific analytes is
discussed. Former lab members optimized the SL library general sequence (R-X-D*-X27

X-X-D*-X-B-B-R-M) and the general library screening procedure. While the SLs that
were discovered through previous screenings were useful in discriminating colon cancer
cell lines, they did not discriminate prostate cell lines with the same classification
accuracy. Screening the library against prostate cell membrane extracts, which contained
the membrane proteins and glycoproteins from prostate cells, identified new SLs (SL1014). Once the SLs binding to the analytes had been isolated, the bound glycoproteins
were removed and sequenced. Due to instrumentation complications, the MALDI,
technique used by former lab members to sequence the SLs, could not be used and
Edman Degradation was used instead. SL10, 13, and 14 were isolated from library
screenings against single analytes such as RWPE-1 (non-cancerous) and PC3 (cancerousmetastatic). SL11 and SL12 were isolated from library screenings against the two single
analytes combined together. In order to see the selectivity for one analyte versus another,
the analytes were labeled with different fluorophores. Once the new SLs were
resynthesized, Orbitrap was used to validate the overall structure of the SLs. Instead of
just two PBA groups located on the fixed Dab positions, a third was also present on the
N-terminus end of the peptide.
2.8 EXPERIMENTAL METHODS
Chemicals
All AA and HBTU were purchased from EMD Millipore. Prostate Specific
Antigen was purchased from Sigma-Aldrich. TentaGel resin (Cat. No. MB-300-002;
loading level 0.25-0.3 mmol/g) was purchased from Rapp Polymere. All other chemicals
were purchased from Acros Organics and used without further purification.
Microscope Usage
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A Leica MZ 16F microscope was used to evaluate the binding of SLs and analytes
of interest. A GFP3 filter set with an excitation 450-490 nm and emission 500-550 nm.
Images were taken using a QImaging MicroPublisher 5.0 RTV digital camera associated
with the microscope. Images were analyzed by MATLAB, which provided SL
fluorescence information.
Library Synthesis
The general sequence of the library was R-X-D*-X-X-X-D*-X-B-B-R-M-Bead,
which means that the first four amino acids were the same for all the beads in the library.
The first AA, methionine, was attached manually by activating FMOC-met-OH in a 5%
N-methylmorpholine in DMF solution and then mixing the AA solution with Tentagel
resin beads (300 µm). After incubating the AA solution with the beads for roughly an
hour, the AA solution was removed and a ninhydrin test was preformed to confirm that
the AA had coupled to the bead. If the ninhydrin test was positive, the beads were put
onto the Protein Technologies Peptide Synthesizer (PS3) where the next 3 AAs (R, B, B)
were coupled to the library of beads. After the beads were removed from the PS3, the
random AA was coupled to the beads using a split-and-pool method. Briefly, the beads
are split into 11 different reaction vessels. In each vessel, a different activated AA is
coupled to the beads. The beads are then combined back into one vessel and deprotected.
Because the next position is fixed with Dab, the beads are coupled to the AA and
deprotected in the same vessel. The next 6 AAs are coupled depending on the fixed or
random position of that particular AA.
Once all of the AAs are coupled, the ivDde protecting group of D* is removed by
using a 5% hydrazine in DMF solution. This deprotection solution also deprotects the last
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FMOC protecting group on the final R of the peptide sequence. The PBA functional
groups are added through reductive amination by incubating the beads with a 2% MeOH
in DMF solution containing an 8 equivalent ratio of bead to 2-formylphenyl boronic acid.
The remaining side-chain protecting groups are removed using a 95% TFA, 2.5% TIS,
and 2.5% H2O.
MS/MS Analysis
To cleave the peptide from the resin, the beads were treated with 50 μl of 40
mg/ml CNBr in 0.1 M HCl for 16 hr in the dark. The beads were removed from the
solution and the excess CNBR, TFA, and water were removed under reduced pressure by
using an AES1010 SpeedVac system. The cleaved peptides were re-dissolved in 10 μl of
0.1% TFA in water. 1 μl of matrix containing saturated α-cyano-4-hydroxycinniamic
acid (CHCA) in 50:50:0.1 acetonitrile/water/TFA was positioned on to a MALDI plate
and mixed with 2 μl of the cleaved SL solution.

Samples were then analyzed by

MALDI-TOF/MS and MS/MS techniques.
Cell Culture
VWR was the supplier for all supplements and media for all cell lines. The media
for RWPE-1 was K-SFM supplemented with recombinant human Epidermal Growth
Factor (rhEGF) and Bovine Pituitary Extract (BPE). The media for PC3 was RPMI 1640
with 10% FBS. The cells were grown in T75 flasks at 37 degrees Celsius.
PBS
To make a 4L solution of PBS, sodium phosphate monobasic (monohydrate) (27.6
g, 200 mmol), sodium phosphate dibasic (anhydrous) (28.4 g, 200 mmol) and sodium
chloride (35.06 g, 600 mmol) was dissolved in 3.5 L of DI water. The pH was adjusted to
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7.2-7.3 using 3 M NaOH and then the solution was diluted to 4L by adding DI water.
Fluorescent Labeling of Prostate Cell Membrane Extracts
The Qiagen Plasma Membrane Protein Kit was used to extract plasma membrane
proteins and glycoproteins. The extract was spun into carbonate buffer pH 9.8 and a BCA
assay was performed to obtain the concentration of the extract. The amount of protein
needed for library screening was added to carbonate buffer to a total volume of 600 µL.
Depending on which dye was being used to label, 0.07 µmol NHS-fluorescein or NHSrodamine was added and the solution was incubated at 37°C and tumbled for 1 hr.
Amicon Pro Centrifugal Filter (10 kDa) were used to remove excess dye and to
concentrate the proteins and glycoproteins after the 1 hr incubation.
BCA Assay
The Thermo Scientific BCA kit was purchased from VWR. A serial dilution of
the BCA 2 mg/mL standard was used for the analysis. Standards and samples (10 µL)
were placed in a 96 well plate in triplicate and combined with 200 µL of the reagent from
the BCA kit. After the wells had been mixed thoroughly, plate was incubated in an oven
for approximately 30 minutes at 370C. The absorbance of the wells was read on a plate
reader at 562 nm.
Library Screening for Single Analytes
Approximately 2 mg of library resin was rinsed in PBS twice and then preincubated with 1% BSA in PBS with 10% glycerol for 15 minutes. This pre-incubation
was to reduce the nonspecific binding between the SL and proteins. The 1% BSA in PBS
with 10% glycerol solution was then removed from the beads and 1 mL of a 0.0002
mg/mL solution of the fluorescently-labeled prostate membrane extract in PBS was
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incubated with the beads for 6 hrs at room temperature with gentle shaking. After
incubation, the beads were rinsed with PBS three times and imaged with a fluorescent
microscope, Leica MZ 16F.
Library Screening Dual Dye Analytes
The library screening for dual dye analytes compared to single analytes were
almost completely identical. The only significant difference was the amount of each
analyte that was used for the study. Instead of using 1 mL containing 0.0002 mg of both
analytes to give a total concentration of 0.0004 mg/mL of protein, only 0.0001 mg was
use of each to make a total concentration of 0.0002 mg/mL.
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CHAPTER 3:
PROSTATE SELECTED SYNTHETIC LECTINS
3.1 CROSS-REACTIVITY WITH PROSTATE CELL LINES
Previously, SLs that were isolated through library screenings against purified
glycoproteins PSM and OVA were found to be cross-reactive to purified glycoproteins as
well as cancer associated glycans and colon cancer cell lines. It is important to mention
that the cross-reactivity of the SLs is what gives the SL array the ability to discriminate
the different glycoproteins they interact with. In order to evaluate the selectivity or crossreactivity of SL10-14 identified in Chapter 2, the SLs were resynthesized using the same
general library synthesis methods as discussed in Chapter 2.
As seen in Figure 3.1, SL10-14 are cross-reactive to 6 prostate cell lines with
varying metastatic potential. The prostate cell lines used can be found in Table 3.1
Table 3.1 Prostate cell lines with metastatic potential listed.
Cell Line

Tissue Type

Metastatic Potential

RWPE-1

Prostate

Non-Cancerous

WPE1-NA22

Prostate

Cancerous/Non-Metastatic

WPE1-NB14

Prostate

Cancerous/Non-Metastatic

LNCaP

Prostate

Cancerous/Metastatic

DU145

Prostate

Cancerous/Metastatic

PC3

Prostate

Cancerous/Metastatic
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While some SLs interact more with one cell line over another (e.g. SL10 binding
with WPE1-NB14 vs. its binding with DU145), not one is selective for one prostate cell
line. Each SL binds cross-reactively to the prostate cell lines.

SL10-14 Prostate Cell Line Cross-Reactivity
1.2
1

RWPE-1

0.8

WPE1-NA22

0.6

WPE1-NB14
LNCAP

0.4

DU145

0.2

PC3

0
SL10

SL11

SL12

SL13

SL14

Figure 3.1 Binding patterns/ “Fingerprint patterns” of SL10-14 with prostate cell lines.
3.2 SL10-14 PROSTATE CELL LINE DISCRIMINATION
As mentioned before in Chapter 1, because it is difficult to see how the SLs are
binding differently to cell lines, LDA is the statistical analysis used to better understand
the similarities and differences in the data above. When using LDA, SL10-14
discriminated prostate cell lines with 83% classification accuracy (Figure 3.2).
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Figure 3.2 LDA plot of SL10-14 classified by prostate cell line.
While it is beneficial to have an array that can correctly identify the different cell
lines present, it is more important to evaluate the array’s ability to distinguish the cell
lines’ metastatic potential when developing a cancer screening array.
When discriminating the prostate cell lines by metastatic potential (Table 3.2) the
classification accuracy was 92% (Figure 3.3). By incorporating the SLs in the former SL
array, SL1, 3, 4, and 5, into an array with the new SLs, the classification accuracy
increases to 100% (Figure 3.4).
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LDA of SL10-14 by Metastic Potential
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Figure 3.3 LDA of SL10-14 classified by metastatic potential.
LDA of SL1,3,4,5 and SL10-14 with Prostate by Metastatic Potential
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Figure 3.4 LDA of SL1, 3, 4, 5 and SL10-14 Prostate by metastatic potential.
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3.3 PROSTATE CANCER VS. COLON CANCER
An ideal cancer diagnostic would not only be able to diagnose the severity of the
disease but also what kind of cancer is present. Using the prostate and colon cell lines in
Table 3.2, LDA was used to discriminate the two types of tissue. When using the SL
array found by former lab members (SL1, 3, 4, and 5) the classification accuracy was
66%. When using the prostate selected SLs, the classification accuracy increased to 95%.
The combined arrays were able to discriminate between prostate cell lines and colon cell
lines with 97% classification accuracy. This information suggests that the prostate
selected SLs bind to the glycoproteins from the two types of tissues in different ways.
Table 3.2 Prostate and colon cell lines with metastatic potential listed.
RWPE-1
CCD 841 CoN
WPE1-NA22
WPE1-NB14
HCT 116
HT-29
LNCAP
DU145
PC3
LoVo

Type of Tissue
Prostate
Colon
Prostate
Prostate
Colon
Colon
Prostate
Prostate
Prostate
Colon

Metastatic Potential
Non-Cancerous
Non-Cancerous
Lowly Metastatic
Lowly Metastatic
Lowly Metastatic
Lowly Metastatic
Highly Metastatic
Highly Metastatic
Highly Metastatic
Highly Metastatic

3.4 THE UTILITY OF SL11
LDA provides more information than just classification accuracies. It can also
information about which SL is most important for discrimination. It provides this
information through an F-to-remove value, which is a value that describes the variables
importance in the discrimination being performed37. If the variable with a large F-toremove was removed from the analysis, the discrimination accuracy would decrease. In
all of the analyses, SL11 always had a high F-to-remove value.
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To see just how powerful SL11 is in discriminating the prostate cell lines, LDA
was used to get classification accuracies. Each analysis was SL11 discriminating one cell
line vs. a different cell line. The results are listed in Table 3.3.
SL11 can discriminate all of the cell lines with high classification accuracies
except for distinguishing WPE1-NA22 from DU145 and LNCaP from PC3. What is the
most important to note is that SL11 has high classification accuracies for distinguishing
the non-cancerous cell line from all of the other cell lines regardless of their varying
metastatic potential.
Table 3.3 Classification matrix for SL11 with prostate cell lines generated by LDA.
RWPE-1
WPE1-NA22
WPE1-NB14
LNCAP
DU145
PC3

RWPE-1
NA
97
100
100
92
100

WPE1-NA22
97
NA
100
100
60
100

WPE1-NB14
100
100
NA
74
97
70

LNCaP
100
100
74
NA
97
57

DU145
92
60
97
97
NA
97

PC3
100
100
70
57
97
NA

3.5 TWO PBA VS. THREE PBA
In order to sequence hits, the synthesis of the library had to be altered from
previous libraries. After resynthesizing the hits found from screening against prostate
membrane proteins and glycoproteins, Orbitrap MS data confirmed there were three PBA
groups attached to the peptide backbone instead of two PBA groups. Because the PBA
groups interact with the sugars present on the glycoproteins, it is important to understand
how the new SL structure plays a role in discriminating cell lines.
When using the prostate selected SLs with 2 boronic acid groups (SL10 2BASL14 2BA) to discriminate the prostate cell lines (Figure 3.5), the classification accuracy
decreased from 92% (using SL10-14 with 3 boronic acid groups) to 86%. By
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incorporating another boronic acid group to the SL sequence, the SLs have more possible
interactions with the glycans present.
LDA of SL10 2BA-SL14 2BA by Metastatic Potential
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Figure 3.5 LDA plot of SL10 2BA-SL14 2BA classified by metastatic potential.
3.6 CONCLUSION
In this chapter, the prostate selected SLs that were isolated and characterized in
Chapter 2 have been resynthesized and bound to analytes of interest. The prostate
selected SL array (SL10-14) has the ability to discriminate 6 prostate cell lines with 83%
classification accuracy. While it is important to be able to distinguish between the cell
lines, it is more important to be able to discriminate the prostate cell lines by metastatic
potential. The SL array had a 92% classification accuracy when discriminating the
prostate cell lines by metastatic potential (non-cancerous, cancerous/non-metastatic, and
cancerous/metastatic). By incorporating the SLs isolated by former lab members into the
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prostate selected SL array, the classification accuracy of prostate cell lines by metastatic
potential increased to 100%.
The prostate selected SL array also has the ability to distinguish between prostate
cell lines and colon cell lines. This is a powerful tool when designing a diagnostic. Not
only is it important to be able to tell a patient if they have cancer or not, but also to tell
them what kind of cancer they have. When using the prostate selected SL array, the
classification accuracy for prostate cell lines vs. colon cell lines was 95%. This was a
significant increase from the previous SL array, which had a classification accuracy of
66%.
SL11 was a particularly important variable in all of the analyses discussed. It
always had a high f-to-remove value, which suggests that if it were taken out of the
analysis, the discrimination accuracy would decrease. SL11, when used by itself to
discriminate between any two prostate cell lines, had high classification accuracies
barring two analyses. In particular, SL11 had high classification accuracies when
distinguishing the non-cancerous cell line RWPE-1 from any other prostate cell line. In
further studies, it would be interesting to discover what glycans SL11 interacts with based
on these results.
Lastly, due to sequencing issues discussed in Chapter 2, the SL hits isolated from
screenings against prostate membrane proteins and glycoproteins contained 3 boronic
acid functional groups instead of two boronic acid groups. The former SL array contained
only two boronic acid groups. In order to see if the amount of boronic acid functional
groups plays a role in discrimination, the two different arrays (SL10-14 with 3 boronic
acids groups and SL10-14 with 2 boronic acids groups) were compared. When using the
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prostate selected SL array, the classification accuracy of the prostate cell lines was 92%.
When using the modified array, which contained only two boronic acids, the
classification accuracy drops to 86%. These results suggest that amount of boronic acid
functional groups are important for the discrimination of prostate cell lines.
3.7 EXPERIMENTAL METHODS
Chemicals
All AA and HBTU were purchased from EMD Millipore. Prostate Specific
Antigen was purchased from Sigma-Aldrich. TentaGel resin (Cat. No. MB-300-002;
loading level 0.25-0.3 mmol/g) was purchased from Rapp Polymere. All other chemicals
were purchased from Acros Organics and used without further purification.
Microscope Usage
A Leica MZ 16F microscope was used to evaluate the binding of SLs and analytes
of interest. A GFP3 filter set with an excitation 450-490 nm and emission 500-550 nm.
Images were taken using a QImaging MicroPublisher 5.0 RTV digital camera associated
with the microscope. Images were analyzed by MATLAB, which provided SL
fluorescence information.
Cell Culture
VWR was the supplier for all supplements and media for all cell lines. All cells
were grown in T75 flasks at 37 °C in 5% CO2 and 95% air. The media for RWPE-1 was
K-SFM supplemented with recombinant human Epidermal Growth Factor (rhEGF) and
Bovine Pituitary Extract (BPE). The media for PC3 was RPMI 1640 with 10% FBS.
LoVo human colorectal carcinoma cells were grown in RPMI 1640 with 10% FBS.
General SL Synthesis Method

41

TentaGel resin (200 mg, 0.05 mmol) was swollen in 10 mL of DMF for 10 min.
The DMF was removed and Fmoc-Met-OH (4 eq, 74.3 mg, 0.2 mmol) preactivated with
HBTU (4 eq, 75.9 mg, 0.2 mmol) for 10 min in 10 mL of 5% N-methylmorpholine in
DMF, was then added. The resin was then tumbled for 1 hr. The amino acid solution
was removed by vacuum filtration and the resin was then washed with DMF, MeOH,
DMF, and MeOH. Ten mL of a 20% piperidine in DMF solution was then added to
remove the Fmoc group. The same procedure was used to subsequently couple the
remaining amino acids in the sequence.
Two PBA SL Synthesis
After the peptide backbone had been coupled to the resin and the last AA
(arginine) was Fmoc deprotected, the peptide was the N-terminally acetylated by
tumbling the resin in 10 mL of CH2Cl2 containing 5% acetic anhydride and 5% pyridine.
Three BA SL Synthesis
Once the peptide backbone had been coupled to the resin and before the last AA
(arginine), ivDde was deprotected using a 5% hydrazine in DMF solution. The Fmoc
protecting group on the last AA was not deprotected with 20% piperidine in DMF before
the ivDde deprotection.
Deprotection of ivDde Protecting Group
The ivDde protecting group of the Dab was removed by tumbling the resin in 10 mL of
5% hydrazine monohydrate in DMF (v/v) for 1 hr after the peptide backbone had been
coupled to the resin.
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Incorporation of PBA
2-formylphenyl boronic acid (8 eq, 119.95 mg, 0.8 mmol) was dissolved in 10% MeOH
in DMF. The boronic acid solution and activated 3Å molecular sieves was then added to
the resin and was tumbled overnight at 37°C. NaBH4 (8 eq, 30.26 mg, 0.8 mmol) was
then added. Gas was evolved for 30 min and the resin was tumbled for 4 hr. Resin was
then washed with DMF, MeOH, DMF, and MeOH. Molecular sieves removed and
washed again.
Removal of Acid-labile Protecting Groups
The resin was tumbled in 10 ml of 95% TFA, 2.5% water, and 2.5% TIS for 1 hr.
The solution was removed by vacuum filtration and the resin was washed with DMF,
MeOH, DMF, and MeOH.
MS/MS Analysis
To cleave the peptide from the resin, the beads were treated with 50 μl of 40
mg/ml CNBr in 0.1 M HCl for 16 hr in the dark. The beads were removed from the
solution and the excess CNBR, TFA, and water were removed under reduced pressure by
using an AES1010 SpeedVac system. The cleaved peptides were re-dissolved in 10 μl of
0.1% TFA in water. 1 μl of matrix containing saturated α-cyano-4-hydroxycinniamic
acid (CHCA) in 50:50:0.1 acetonitrile/water/TFA was positioned on to a MALDI plate
and mixed with 2 μl of the cleaved SL solution.

Samples were then analyzed by

MALDI-TOF/MS and MS/MS techniques.
PBS
To make a 4L solution of PBS, sodium phosphate monobasic (monohydrate) (27.6 g, 200
mmol), sodium phosphate dibasic (anhydrous) (28.4 g, 200 mmol) and sodium chloride
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(35.06 g, 600 mmol) was dissolved in 3.5 L of DI water. The pH was adjusted to 7.2-7.3
using 3 M NaOH and then the solution was diluted to 4L by adding DI water.
Fluorescent Labeling of Prostate Cell Membrane Extracts
The Qiagen Plasma Membrane Protein Kit was used to extract plasma membrane
proteins and glycoproteins. The extract was spun into carbonate buffer pH 9.8 and a BCA
assay was performed to obtain the concentration of the extract. The amount of protein
needed for library screening was added to carbonate buffer to a total volume of 600 µL.
Depending on which dye was being used to label, 0.07 µmol NHS-fluorescein or NHSrodamine was added and the solution was incubated at 37°C and tumbled for 1 hr.
Amicon Pro Centrifugal Filter (10 kDa) were used to remove excess dye and to
concentrate the proteins and glycoproteins after the 1 hr incubation.
BCA Assay
The Thermo Scientific BCA kit was purchased from VWR. A serial dilution of
the BCA 2 mg/mL standard was used for the analysis. Standards and samples (10 µL)
were placed in a 96 well plate in triplicate and combined with 200 µL of the reagent from
the BCA kit. After the wells had been mixed thoroughly, plate was incubated in an oven
for approximately 30 minutes at 370C. The absorbance of the wells was read on a plate
reader at 562nm.
Binding Studies with Fluorescent-labeled Membrane Extracts
Approximately 2 mg of SL was rinsed in PBS twice and then pre-incubated with
1% BSA in PBS with 10% glycerol for 15 minutes. This pre-incubation was to reduce the
nonspecific binding between the SL and proteins. The 1% BSA in PBS with 10%
glycerol solution was then removed from the beads and 1 mL of a 0.0002 mg/mL solution
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of the fluorescently-labeled prostate membrane extract in PBS was incubated with the
beads for 6 hrs at room temperature with gentle shaking. After incubation, the beads were
rinsed with PBS three times, imaged with a fluorescent microscope, Leica MZ 16F, and
analyzed by Matlab R2012a. The output was analyzed by linear discriminant analysis
using SYSTAT 11.00.01.
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CHAPTER 4:
OPTIMIZATION OF DATA ACQUISITION
4.1 SL ARRAY DATA ACQUISITION
As stated in Chapter 1, cancer diagnostics are not ideal and a novel, facile, and
efficient procedure needs to be created to increase patient survival rates. The SL arrays
that have been discussed throughout this dissertation have the potential to diagnose
cancer with high accuracies and during the early stages of cancer, when it is most
treatable. One important component of the SL array diagnostic is data acquisition.
4.2 OBTAINING DATA FOR MATLAB
Through standard Fmoc protocols and HBTU activation, the four SLs (Table 4.1)
used in the colon cancer array were re-synthesized and verified by matrix assisted laser
desorption/ionization (MALDI).
Table 4.1 SL sequences used in colon cancer array.
SL Hit

Sequence

SL1

Ac-R-G-D*-V-T-F-D*-R-B-B-R-M-resin

SL3

Ac-R-S-D*-V-T-T-D*-R-B-B-R-M-resin

SL4

Ac-R-R-D*-T-Q-T-D*-Q-B-B-R-M-resin

SL5

Ac-R-A-D*-T-R-V-D*-V-B-B-R-M-resin

Three colon cell lines analyzed by previous lab members along with two new
breast cell lines (Table 4.2) were grown in T75 flasks at 37°C in 5% CO2 and 95% air.

46

Table 4.2 Colon and breast cell lines with metastatic potential listed.
Cell Line

Tissue Type

Metastatic Potential

3T3/NIH

Colon

Non-Cancerous

CT26

Colon

Cancerous/Non-Metastatic

LoVo

Colon

Cancerous/Metastatic

MCF10A

Breast

Non-Cancerous

MCF7

Breast

Cancerous/Non-Metastatic

After the cells had grown to 70-75% confluence, the cells were scraped and
treated with the Qiagen Plasma Membrane Protein Kit to extract plasma membrane
proteins and glycoproteins. The extracts were labeled with fluorescence isothiocyanate
(FITC) and then dialyzed against screening buffer.
SL1, 3, 4, and 5 were first washed with phosphate buffered saline (PBS). The
beads were then incubated with 1% bovine serum albumin (BSA) to decrease nonspecific binding. After 15 minutes, the beads were then incubated with FITC labeled
membrane extracts for 6 hours. The SLs were washed three times and imaged with a
Leica MZ 16F microscope with a GFP filter set. Matlab™ R2012a analyzed the images
and the data produced was analyzed by SYSTAT™.
4.3 MATLAB
While Matlab™ eases the process of analyzing the images taken, there are many
sources of error that are present. The beads are suspended on the slides in PBS so some
beads could be floating while other beads might be resting on the microscope slide
making some beads look out of focus and not as bright. The camera that is used may also
have burned out pixels that the Matlab™ program could identify as a bead that is bright.
Also, the lamp that is used is circular while the image that is taken is rectangular meaning
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that the beads that fall in the outer area of the frame can appear to be less bright due to a
decrease in binding with the glycoproteins but that is not the case. With all of these
errors, there can be parameters adjusted in the Matlab™ program that enable the source
of error to be eliminated.
4.4 REGION OF INTEREST
The first parameter that was considered was the region of interest (ROI) feature.
The ROI places a set area that Matlab™ picks the bright beads from which can allow the
program to exclude the beads that fall in the outer areas of the frame that appear to be not
as bright. The three colon cell lines (3T3/NIH, CT26, and LoVo) were analyzed twice by
Matlab™, once with and once without the ROI. Classification accuracies increase by
19% (70% without an ROI, Figure 4.1, and 89% with an ROI, Figure 4.2) when the ROI
is used on the images. These results show that using the ROI and excluding the beads that
fall in the edges of the image are important for better classification accuracies.
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Figure 4.1 LDA plot for discrimination of three colon cancer cell lines by metastatic
potential. This analysis was based on data acquisition without an ROI.
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Figure 4.2 LDA plot for discrimination of three colon cancer cell lines by metastatic
potential. This analysis was based on data acquisition with an ROI.
4.5 COLOR SPACES
The second parameter investigated was the red, green, and blue color spaces in the
color of the bead. Previous lab members did not have the Matlab program so they had to
pick bright beads manually and record its luminosity using Adobe Photoshop™.
Matlab™ picks the bright beads and records the luminosity as well as the intensities in
the red, green, and blue color spaces. By using all of the red, green, and blue intensities,
the number of independent variables increases which increases the SL array’s ability to
discriminate the cell lines with greater classification accuracy (a 14% increase) (Figure
4.3 and Figure 4.4). The variables are independent because of fluorescein’s
solvatochromism and the background contributions to the spectrum. These results show
that using the red, green, and blue color spaces are important for higher classification
accuracies.
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Figure 4.3 LDA plot for discrimination of three colon cancer cell lines by metastatic
potential. This analysis was based on data acquisition using only bright numbers.
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Figure 4.4 LDA plot for discrimination of three colon cancer cell lines by metastatic
potential. This analysis was based on data acquisition using all three color spaces.
4.6 CONCLUSION
Because the current SL array seems to discriminate better by metastatic potential,
colon and breast cell lines were discriminated by metastatic potential to see if the array
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has the ability to be used on other cell lines or if it is specific to colon cancer. The array
had a classification accuracy of 88% when distinguishing the metastatic potential of five
cell lines originating from different tissues and 97% accuracy when distinguishing the
two breast cell lines. These results show that the array can discriminate colon and breast
cell lines.
4.7 EXPERIMENTAL METHODS
Synthesis of Synthetic Lectins.
For example, TentaGel resin (200 mg, 0.05 mmol) was swollen in 10 ml of
Dimethylformamide (DMF) for 10 min. The DMF was removed and Fmoc-Met-OH (4
eq, 74.3 mg, 0.2 mmol) preactivated with HBTU (4 eq, 75.9 mg, 0.2 mmol) for 10 min in
10 ml of 5% N-methylmorpholine in DMF, was then added. The resin was then tumbled
for 45 min at 37°C. The amino acid solution was then removed by vacuum filtration and
the resin was then washed with DMF, methanol (MeOH), DMF, and MeOH. 10 ml of a
20% piperidine in DMF solution was then added to remove the Fmoc group. The same
procedure was used to subsequently couple the remaining amino acids in the sequence.
The peptide was the N-terminally acetylated by tumbling the resin in 10 ml of CH2Cl2
containing 5% acetic anhydride and 5% pyridine.
Deprotection of ivDde Protecting Group.
The ivDde protecting group of the diamino acid Dab was removed by tumbling
the resin in 10 ml of 2% hydrazine monohydrate in DMF (v/v) for 1 hr.
Incorporation of Phenyl Boronic Acid (PBA).
2-formylphenyl boronic acid (8 eq, 119.95 mg, 0.8 mmol) was dissolved in 10% MeOH
in DMF. The boronic acid solution and activated 3Å molecular sieves was then added to
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the resin and was tumbled overnight at 37°C. NaBH4 (8 eq, 30.26 mg, 0.8 mmol) was
then added. Gas was evolved for 30 min and the resin was tumbled for 4 hr. Resin was
then washed with DMF, MeOH, DMF, and MeOH. Molecular sieves removed and
washed again.
Removal of Acid-labile Protecting Groups.
The resin was tumbled in 10 ml of 95% trifluoroacetic acid (TFA), 2.5% water,
and 2.5% triisopropylsilane (TIS) for 1 hr.

The solution was removed by vacuum

filtration and the resin was washed with DMF, MeOH, DMF, and MeOH.
MS/MS analysis.
To cleave the peptide from the resin, the beads were treated with 50 μl of 40
mg/ml CNBr in 0.1 M HCl for 16 hr in the dark. The beads were removed from the
solution and the excess CNBR, TFA, and water were removed under reduced pressure by
using an AES1010 SpeedVac system. The cleaved peptides were re-dissolved in 10 μl of
0.1% TFA in water. 1 μl of matrix containing saturated α-cyano-4-hydroxycinniamic
acid (CHCA) in 50:50:0.1 acetonitrile/water/TFA was positioned on to a MALDI plate
and mixed with 2 μl of the cleaved SL solution.

Samples were then analyzed by

MALDI-TOF/MS and MS/MS techniques.
Cell Culture.
All cells were grown in T75 flasks at 37°C in 5% CO2 and 95% air. CT-26 colon
carcinoma cells and MCF7 human breast cancer cells were grown in Dulbecco’s
Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic. NIH/3T3 murine fibroblast cells were grown in DMEM with 10%
neonatal calf serum and 1% antibiotic/antimycotic. LoVo human colorectal carcinoma

52

cells were grown in Roswell Park Memorial Institute (RPMI) media with 10% FBS and
1% antibiotic/antimycotic. MCF10A human breast cells were grown in DMEM/Nutrient
F-12 Ham (DMEM/F12) with 5% horse serum, 10 μg/ml of insulin, 20 ng/ml of
epidermal growth factor (EGF), 100 ng/ml of cholera toxin, and 0.5 μg/ml
hydrocortisone.
FITC-labeling Cell Membrane Extracts.
After cells were grown to 80% confluence, the corresponding media was added
and cells were scraped. The cells were then collected in 50 ml centrifuge tubes from four
T75 flasks and centrifuged. Media was removed and PBS buffer was used to wash the
cell pellets two times. The Qiagen Plasma Membrane Protein Kit was used to extract
plasma membrane proteins and glycoproteins. The pH of the 2 ml extraction solution
was adjusted to 8.8. FITC (.07 μmol, 28 μg) in DMF (5.3 μl) was incubated at 37°C for
1 hr. The solution was then transferred to a 3.5 kDa Slide-A-Lyzer cassette and dialyzed
against 500 ml of screening buffer (100 mM NaH2PO4, 150 mM NaCl, 10% glycerol, pH
7.2) at 4°C. Screening buffer was changed every 6-8 hr 3 times. FITC-labeled extracts
were collected and concentrations were obtained through Absorbance and fluorescence
analysis.
General procedure for the SL array.
2 mg of each SL were weighed in 1.5 ml microcentrifuge tubes and rinsed with 1
ml of PBS buffer for 10 min. The PBS buffer was then removed and the beads were
incubated in 1% BSA for 15 min to reduce non-specific binding. The beads were then
treated with 1 ml of 20 fold dilutions of FITC-labeled cell membrane extracts and
tumbled for 6 hr at room temperature. Beads were then washed with PBS three times,
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imaged with a Leica MZ 16F microscope with a GFP filter set, and analyzed by Matlab
R2012a.

The output was analyzed by linear discriminant analysis using SYSTAT

11.00.01.
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CHAPTER 5
CONCLUSION
Aberrant glycosylation takes place during the onset of cancer and throughout the
progression of the disease allowing certain glycans to serve as biomarkers1. Boronic acid
functionalized synthetic lectins (SLs) have been shown to bind selectively and crossreactively to certain glycoproteins through covalent yet reversible interactions between
the boronic acids and 1,2- or 1,3-diols found on saccharides2.
In chapter 2, an SL library was screened against fluorescently-labeled prostate
membrane glycoproteins and proteins in order to create a prostate specific array. This was
achieved by screening with fluorescently labeled prostate membrane proteins and
glycoproteins. The hits selected using the aforementioned screening method, were
resynthesized and incubated with prostate cell lines with varying metastatic potentials as
well as colon cell lines with varying metastatic potentials, as seen in Chapter 3. The
results indicated that when using the prostate selected SLs classification accuracies were
high for the discrimination of prostate cell lines by metastatic potential. Classification
accuracy improved when including these prostate selected SLs with the previous SL array
with colon and prostate cell lines.
The last piece of this project involved investigating data acquisition parameters
and how these could be adjusted in order to obtain the most accurate representation of the
SL–glycoprotein interaction. This was achieved through including a region of interest
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(ROI) as well as using all color spaces when collecting data from fluorescent images
captured.
There are many different directions that the SL array can move towards in the
future. The arrays should be applied to more types of cancers to assess the versatility of
the arrays’ differentiation abilities. It is important to evaluate the current SLs’ binding
affinities for different cancer associated glycans in order to optimize the SL array. Also,
the new library screening discussed in this dissertation can be used to find SLs with
greater selectivity. The results presented in this dissertation highlight the immense
potential of SL arrays as tools in cancer diagnostics.
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APPENDIX A:
SL IMAGING MATLAB CODE
This Appendix is the MATLAB code written by Dr. Greytak that was used to
analyze images taken of the SLs. He incorporated many different features that could be
used for different types of analyses. Even though the complete code is below, only certain
sections are used for SL image analysis. The black lines separate the sections. Sections
that are not used in the analysis are in light blue and should be skipped when running the
MATLAB program.
% For analysis images of silica particles
% 7/11/2012
_______________________________________________________________________
%% setup
% Define colormaps (all length 256)
redmap=zeros(256,3);
redmap(:,1)=linspace(0,1,256);
greenmap=zeros(256,3);
greenmap(:,2)=linspace(0,1,256);
bluemap=zeros(256,3);
bluemap(:,3)=linspace(0,1,256);
ratiomap=zeros(256,3);
ratiomap(1:128,1)=linspace(0,1,128);
ratiomap(129:256,1)=1;
ratiomap(1:128,2)=1;
ratiomap(129:256,2)=linspace(1,0,128);
ratiomap(1,:)=0;
ratio_min=0.0;
ratio_max=1.0;
ratiolevels=linspace(ratio_min,ratio_max,101);
ratiolevels=(ratiolevels(2:end) + ratiolevels(1:end-1))./2;
% sets the bins used to track pixel or average brightness
levels=0:255;
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% levels=(levels(1:end-1)+levels(2:end))./2; % gets midpoints between
level centers
% set thresholding values to exclude dark and/or saturated regions
red_squelch=0;
red_limit=+Inf;
% green_squelch=0;
% green_limit=+Inf;
green_squelch=0;
green_limit=+Inf; % 8-bit image: 255 would definitely be clipping
blue_squelch=0;
blue_limit=+Inf;
% allows you to blur incoming images if they are pixellated
h=1;
% blur_radius=1;
% h=fspecial('gaussian',21,blur_radius);
%
labelstyle='particle'; % 'grid', 'particle', or 'single'
_______________________________________________________________________
%% define dataset
indir='Z:\Huang, Rong\RH 082415 pictures\Pictures After Conversion/';
clear outfile
% comment out below to suppress all output files
outdir=['Z:\Huang, Rong\RH Matlab\082515 RH PC3 rwpe_1 SL11, Mut1 mut2
mut3/'];
outfile='test';

% set up a list of files corresponding to a single (or each) experiment
% experiment 1

files=dir([indir '*.jpg']);
for(i=1:length(files))
inputfile(i).rgbfile=files(i).name;
end
% initialize the (manual) region of interest
clear red merged
roix=[];
roiy=[];
merged=imread([indir inputfile(1).rgbfile]);
red=merged(:,:,1);
myroi=logical(ones(size(red)));
clear red merged files
_______________________________________________________________________
%% Correction factors for inhomogenious illumination/detection
% from 6-12B solution
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%
ff_redfile='\andrew\aaa_svn\z_old\research\work\imaging\80801_rox_analy
sis\ff_red_6_12b.mat';
%
ff_greenfile='\andrew\aaa_svn\z_old\research\work\imaging\80511_mouse_p
H_sensor\ff_red_6_12b.mat';
%
% % load correction factors
% load(ff_redfile);
% load(ff_greenfile);
% create correction factors
% ff_red=mean(red(myroi))./double(red);
% ff_green=mean(green(myroi))./double(green);
%
% % save
% save(ff_redfile,'ff_red');
% save(ff_greenfile,'ff_green');
_______________________________________________________________________
%% index slices required
%
%
%
%
%
%
%

this would let us choose a manual region of interest to use for all
images
for(thelocation=1:length(location))
location(thelocation).myroi=[];
location(thelocation).roix=[];
location(thelocation).roiy=[];
end

% initialize -- set histograms for pixel
(particle
% average) intensities to zero
for(theinputfile=1:length(inputfile))
inputfile(theinputfile).redhist ...
=zeros(size(levels));
inputfile(theinputfile).greenhist ...
=zeros(size(levels));
inputfile(theinputfile).bluehist ...
=zeros(size(levels));
inputfile(theinputfile).brighthist ...
=zeros(size(levels));
inputfile(theinputfile).validlabels ...
=[];
end

intensities

and

label

clear newslice thelocation theslice thefile
_______________________________________________________________________
%% show an image
theinputfile=1;
% myroi=location(currentlocation).myroi;
% roix=location(currentlocation).roix;
% roiy=location(currentlocation).roiy;
titlestr=['Input file ' num2str(theinputfile)];
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% aggregate images
clear red green blue merged
merged=imread([indir inputfile(theinputfile).rgbfile]);
red=merged(:,:,1);
green=merged(:,:,2);
blue=merged(:,:,3);
% merged
figure(1);clf;
%imshow(merged(:,:,:).*(2^16/(double(max(merged(myroi))))))
imshow(merged)
title(titlestr);
text(0.02*max(xlim),0.02*max(ylim),titlestr,'color','w')
% % red slice
figure(2);clf;
%imshow(red,[0 max(stretchlim(red,0.00001))]*2^16)
imshow(red,[0 max(red(myroi))])
colormap(redmap); colorbar;
title(titlestr);
%
% % green slice
figure(3);clf;
%imshow(green,[0 max(stretchlim(green,0.00001))]*2^16)
imshow(green,[0 max(green(myroi))])
colormap(greenmap); colorbar;
title(titlestr)
%
% % blue slice
figure(4);clf;
%imshow(blue,[0 max(stretchlim(blue,0.00001))]*2^16)
imshow(blue,[0 max(blue(myroi))])
colormap(bluemap); colorbar;
title(titlestr)

% display ROI outline
if(exist('roix','var') && length(roix)>2)
for(i=find(ishandle(1:4)))
figure(i);
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
_______________________________________________________________________
%% Pick ROI
myroi=true(size(red)); % initialize all-on, pick subregion only if we
want
roix=[];
roiy=[];
% uncomment if you want to pick a subregion
delete(findall(gcf,'type','line'));
[myroi roix roiy]=roipoly;
% display ROI outline
if(length(roix)>2)
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line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
_______________________________________________________________________
%% Reset ROI
myroi=true(size(red)); % initialize all-on, pick subregion only if we
want
roix=[];
roiy=[];
_______________________________________________________________________
%% Save an ROI
save annas_roi myroi roix roiy
_______________________________________________________________________
%% Load an ROI
load 'Z:\Veldkamp\Data\2012 Matlab\myroi.mat'
% load myroi ... load Hannah's ROI
% display ROI outline
if(exist('roix','var') && length(roix)>2)
for(i=find(ishandle(1:4)))
figure(i);
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
_______________________________________________________________________
%% compute statistics for each slice
clear red green blue displaymask
myinputfiles=1:276;
% myinputfiles=1:length(inputfile); % all files
showimages=0; % set to 1 if you want it to display each time
saveimages=0; % write labeled images out to output directory ...
doesn't work yet
if(exist('outfile','var'))
if(~exist(outdir,'dir'))
mkdir(outdir);
end
end
particletable=fopen([outdir outfile '_particles.txt'],'w');
% now gather values for selected slices
for(theinputfile=myinputfiles)
% print to command line the index of the file we are currently
studying
fprintf(1,'\n Inputfile %d',theinputfile);
% read data from the current input image of interest
clear red green blue merged label
merged=imread([indir inputfile(theinputfile).rgbfile]);
red=merged(:,:,1);
green=merged(:,:,2);
blue=merged(:,:,3);

%
%

% Gaussian filter -- blur images
red=imfilter(red,h,'replicate');
green=imfilter(green,h,'replicate');
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%

blue=imfilter(blue,h,'replicate');
% Apply correction factors
if(exist('ff_red','var'))
red=uint16(double(red).*ff_red);
end
if(exist('ff_green','var'))
green=uint16(double(green).*ff_green);
end
% Background subtraction
% not used here... ideally uses background image

if(showimages==1)
figure(1);clf
imshow(merged,stretchlim(merged))
titlestr=['Merged: Inputfile ' num2str(theinputfile)
': '
inputfile(theinputfile).rgbfile];
text(0.02*max(xlim),0.02*max(ylim),titlestr,'color','w')
if(exist('roix','var') && length(roix)>2)
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
% Thresholding
% full auto
%
mymask = im2bw(merged,graythresh(merged));
mymask = im2bw(green,graythresh(green));
% threshold based on some multiple of background intensity
bg_factor = 3; % background is anything less than this times the
average
bg_radius = 108; % radius by which we grow the particle mask to
find bg
bg_img=rgb2gray(merged); % grayscale image, could use a channel
bg_mask = ~imdilate(mymask,strel('octagon',bg_radius));
bg_level = mean(bg_img(bg_mask));
mymask = bg_img>(bg_level.*bg_factor);
% manual
mymask = mymask & ...
(red <= red_limit) & (red >= red_squelch) & ...
(green <= green_limit) & (green >= green_squelch) & ...
(blue <= blue_limit) & (blue >= blue_squelch);
% include a manually-chosen region of interest if desired ... if it
% doesn't exist, we create one that includes all of the image
if(~exist('myroi','var'))
myroi=true(size(red)); roix=[]; roiy=[];
end
if(showimages == 1) % display threshold mask and ROI
figure(2);
imshow(mymask & myroi,[]);
titlestr=['mymask & myroi: Inputfile ' num2str(theinputfile)
': ' inputfile(theinputfile).rgbfile];
text(0.02*max(xlim),0.02*max(ylim),titlestr,'color','w')
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% draw ROI box
if(exist('roix','var') && length(roix)>2)
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
% Break image into labeled regions
mylabel=uint16(zeros(size(red)));
switch labelstyle
case 'grid'
% impose 4x4 grid at image center
clear x y
x=floor((0:size(red,2)-1)/(size(red,2)/6));
y=floor((0:size(red,1)-1)/(size(red,1)/6));
x(x>4)=0;
y(y>4)=0;
[x y]=meshgrid(x,y);
x(y==0)=0;
y(x==0)=0;
y=(y-1)*4;
y(y<0)=0;
mylabel=x+y;
clear x y
mylabel(~mymask)=0;
mylabel(~myroi)=0;
case 'particle'
% break image into labeled thresholded islands (e.g.,
cells)
mylabel=bwlabel(mymask);
% we don't kill outside roi for particles: can be more
clever
% below
otherwise
% default (trivial case): single tile for entire image
mylabel(:)=1;
mylabel(~mymask)=0;
mylabel(~myroi)=0;
end
% Display all labeled regions for current slice
if(showimages==1)
figure(3);
titlestr=['All labels: Inputfile ' num2str(theinputfile)
': '
inputfile(theinputfile).rgbfile];
imshow(mylabel.*mymask,[]);colormap('colorcube')
text(0.02*max(xlim),0.02*max(ylim),titlestr,'color','w')
% draw ROI box
if(exist('roix','var') && length(roix)>2)
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
% Compute statistics by pixel (actually just histograms here;
% averages and variances can be determined later for display)
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redhist=hist(red(mymask & myroi),levels);
greenhist=hist(green(mymask & myroi),levels);
bluehist=hist(blue(mymask & myroi),levels);
brightimg=rgb2gray(merged);
brighthist=hist(brightimg(mymask & myroi),levels);
% compute ratio
%
ratio=zeros(size(red));
%
ratio(mymask) = ...
%
double(red(mymask)) ./ (double(red(mymask)) +
double(green(mymask)));
%
ratiohist=hist(ratio(mymask),ratiolevels);

% Compute statistics for all color channels, by label
validlabels=false(1,max(mylabel(:)));
for(j=1:max(mylabel(:)))
if(~(mylabel==j)) % mostly for grid-based labels: skip if no
pixels have this label
continue
end
% get particle properties -- characterize entire particle even
if
% part is OUTSIDE of ROI
% mean intensity
label(j).red=mean(red(mylabel==j));
label(j).green=mean(green(mylabel==j));
label(j).blue=mean(blue(mylabel==j));
label(j).bright=mean(brightimg(mylabel==j));
% std dev within each label
label(j).redstd=std(double(red(mylabel==j)));
label(j).greenstd=std(double(green(mylabel==j)));
label(j).bluestd=std(double(blue(mylabel==j)));
label(j).brightstd=std(double(brightimg(mylabel==j)));
% get percentile values within each label
tolerance=[0.2 0.8];
label(j).redhi=255*max(stretchlim(red(mylabel==j),tolerance));
label(j).greenhi=255*max(stretchlim(green(mylabel==j),tolerance));
label(j).bluehi=255*max(stretchlim(blue(mylabel==j),tolerance));
label(j).brighthi=255*max(stretchlim(brightimg(mylabel==j),tolerance));
labelprops=regionprops((mylabel==j
mymask),'Area','Perimeter','Centroid');
%
label(j).area=labelprops.Area;
label(j).area=sum(mylabel(:)==j); % more reliable: works
disconnected
label(j).perimeter=labelprops.Perimeter;
label(j).circ=4*pi()*(label(j).area/(label(j).perimeter^2));
label(j).centroid=cat(1,labelprops.Centroid);
validlabels(j)=true; % innocent until proven guilty
% disqualify labels that extend outside ROI borders
if(find(mylabel==j & ~myroi))
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&
if

validlabels(j)=false;
end
% disqualify labels that touch ROI edge (including edge of
% image)
if(find(mylabel==j & bwperim(myroi)))
validlabels(j)=false;
end
% disqualify ONLY labels that lie ENTIRELY outide ROI
if(find(mylabel==j & ~myroi))
validlabels(j)=false;
if(find(mylabel==j & myroi))
validlabels(j)=true;
end
end
% disqualify particles that we don't like
if(label(j).area < 5000)
validlabels(j)=false;
end
% disqualify particles with saturated regions
if(label(j).greenhi >=250)
validlabels(j)=false;
end
% disqualify particles on circularity
if(label(j).circ < 0.85)
validlabels(j)=false;
end

%
%
%
%
%
%

end
if(showimages==1 || saveimages==1) % what is this?
myvalidlabel=mylabel;
for(j=1:length(validlabels))
if(validlabels(j) == 0)
myvalidlabel(myvalidlabel==j)=0;
end
end
end
if(showimages==1)
% make a copy of labeled indexed color image, and delete
invalid
% particles
figure(4);
imshow(myvalidlabel,[]);colormap('colorcube')
titlestr=['Valid labels: Inputfile ' num2str(theinputfile)
':
' inputfile(theinputfile).rgbfile];
text(0.02*max(xlim),0.02*max(ylim),titlestr,'color','w')
% draw ROI box
if(exist('roix','var') && length(roix)>2)
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
if(saveimages==1)
% This doesn't work right now.
%
imwrite(ind2rgb(myvalidlabel,'colorcube'),[outdir
outfile '_' num2str(theinputfile,'%.3d') '.png'],'png');
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end

%
%

% Copy values for current image file to inputfile structure
inputfile(theinputfile).redhist ...
=redhist;
inputfile(theinputfile).greenhist ...
=greenhist;
inputfile(theinputfile).bluehist ...
=bluehist;
inputfile(theinputfile).brighthist ...
=brighthist;
inputfile(theinputfile).ratiohist ...
=ratiohist;
inputfile(theinputfile).validlabels ...
=validlabels;
inputfile(theinputfile).label ...
=label;
% print particle statistics to logfile
labelfields=fieldnames(label);

% print header row, if desired, if it hasn't been printed already
if(ftell(particletable)==0)
% tell us if we're at the beginning
of the file
% file name
fprintf(particletable,'Inputfile
',inputfile(theinputfile).rgbfile);
% print file number, particle number, valid yes/no
fprintf(particletable,'FileNo. ParticleNo. Valid ');
% print label data fields
for(k=1:length(labelfields))
fprintf(particletable,'%s ',labelfields{k});
end
% end of line -- formally \n will do but \r\n makes readable in
Notepad
fprintf(particletable,'\r\n');
end
% generate a line for each particle
for(j=1:length(validlabels))
% print input filename, if desired
fprintf(particletable,'%s ',inputfile(theinputfile).rgbfile);
% print file number, particle number, valid yes/no
fprintf(particletable,'%d %d %d ', ...
theinputfile,j,validlabels(j));
% print label data fields
for(k=1:length(labelfields))
fprintf(particletable,'%d ',label(j).(labelfields{k}));
end
% end of line -- formally \n will do but \r\n makes readable in
Notepad
fprintf(particletable,'\r\n');
end
% Build up the union of the masks of (valid) labels for all images,
for
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%

% diagnostic purposes
if( ~exist('displaymask','var') )
displaymask=zeros(size(red));
end
if(exist('displaymask','var') )
% all masks
displaymask=displaymask | (mymask & myroi);
% only valid
for(j=find(validlabels))
displaymask=displaymask | (mylabel==j);
end
end

end
fclose(particletable);
save([outdir outfile '_data.mat'],'inputfile');
if(exist('displaymask','var'))
figure(5);clf
imshow(displaymask)
titlestr=['All labels, all files'];
text(0.02*max(xlim),0.02*max(ylim),titlestr,'color','w')
% draw ROI box
if(exist('roix','var') && length(roix)>2)
line(roix,roiy,'color','w','linestyle','-','linewidth',2);
line(roix,roiy,'color','k','linestyle',':','linewidth',2);
end
end
clear red green blue redhist greenhist bluehist ratiohist
clear validlabels labelratio labelred labelblue labelgreen
clear labelredhist labelgreenhist labelratiohist
clear i j
clear mymask particletable
_______________________________________________________________________
%% Load saved data set -- from current directory, not outdir
load('test_data.mat');
_______________________________________________________________________
%% Display aggregated statistics for a set of slices
% pick slices
myinputfiles=1:4;
titlestr=['Inputfiles
'
num2str(myinputfiles(end))];

num2str(myinputfiles(1))

% initialize totals
redhist=zeros(size(levels));
greenhist=zeros(size(levels));
bluehist=zeros(size(levels));
brighthist=zeros(size(levels));
% ratiohist=zeros(size(ratiolevels));
labelredhist=zeros(size(levels));
labelgreenhist=zeros(size(levels));
labelbluehist=zeros(size(levels));
labelbrighthist=zeros(size(levels));
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'-'

% labelratiohist=zeros(size(ratiolevels));
% aggregate data from all slices
for(theinputfile=myinputfiles)
redhist=redhist ...
+inputfile(theinputfile).redhist;
greenhist=greenhist ...
+inputfile(theinputfile).greenhist;
bluehist=bluehist ...
+inputfile(theinputfile).bluehist;
brighthist=brighthist ...
+inputfile(theinputfile).brighthist;
validlabels=inputfile(theinputfile).validlabels;
% opportunity to adjust choice of valid labels
%
validlabels([inputfile(theinputfile).label(:).area] >
1000)=true;
labelredhist=labelredhist ...
+hist([inputfile(theinputfile).label(validlabels).red],levels);
labelgreenhist=labelgreenhist ...
+hist([inputfile(theinputfile).label(validlabels).green],levels);
labelbluehist=labelbluehist ...
+hist([inputfile(theinputfile).label(validlabels).blue],levels);
labelbrighthist=labelbrighthist ...
+hist([inputfile(theinputfile).label(validlabels).bright],levels);
%
labelratiohist=labelratiohist ...
%
+location(thelocation).time(thetime).slices(theslice).labelratiohist;
end
% compute mean and standard deviation for each metric
redmean=sum(levels.*redhist) / sum(redhist);
redstd= sqrt( sum( redhist.*((levels - redmean).^2) ) ...
/ sum(redhist));
greenmean=sum(levels.*greenhist) / sum(greenhist);
greenstd= sqrt( sum( greenhist.*((levels - greenmean).^2) ) ...
/ sum(greenhist));
% ratiomean=sum(ratiolevels.*ratiohist) / sum(ratiohist);
% ratiostd= sqrt( sum( ratiohist.*((ratiolevels - ratiomean).^2) ) ...
%
/ sum(ratiohist));
labelredmean=sum(levels.*labelredhist) / sum(labelredhist);
labelredstd= sqrt( sum( labelredhist.*((levels - labelredmean).^2) )
...
/ sum(labelredhist));
labelgreenmean=sum(levels.*labelgreenhist) / sum(labelgreenhist);
labelgreenstd=
sqrt(
sum(
labelgreenhist.*((levels
labelgreenmean).^2) ) ...
/ sum(labelgreenhist));
%
labelratiomean=sum(ratiolevels.*labelratiohist)
/
sum(labelratiohist);
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%
labelratiostd=
sqrt(
labelratiomean).^2) ) ...
%
/ sum(labelratiohist));

sum(

labelratiohist.*((ratiolevels

-

% plot data
figure(6);clf;
%
xlimits=[0
max(levels([find(redhist,1,'last')
find(greenhist,1,'last')]))];
% xlimits=[0 500*ceil(max(xlimits)/500)];
xlimits=[0 256];
% pixel data
subplot(2,2,1);
handles=bar(levels,redhist);
set(handles,'FaceColor','r','EdgeColor','none','BarWidth',1.0);
xlim(xlimits);
line([redmean redmean],ylim,'color','k');
subplot(2,2,3);
handles=bar(levels,greenhist);
set(handles,'FaceColor',[0 0.7 0],'EdgeColor','none','BarWidth',1.0);
xlim(xlimits);
line([greenmean greenmean],ylim,'color','k');
%
%
%
%

subplot(3,2,5);
handles=bar(ratiolevels,ratiohist);
set(handles,'FaceColor','k','EdgeColor','none','BarWidth',1.0);
line([ratiomean ratiomean],ylim,'color','r');

% label data
subplot(2,2,2);
handles=bar(levels,labelredhist);
set(handles,'FaceColor','r','EdgeColor','none','BarWidth',1.0);
xlim(xlimits);
line([labelredmean labelredmean],ylim,'color','k');
subplot(2,2,4);
handles=bar(levels,labelgreenhist);
set(handles,'FaceColor',[0 0.7 0],'EdgeColor','none','BarWidth',1.0);
xlim(xlimits);
line([labelgreenmean labelgreenmean],ylim,'color','k');
%
%
%
%

subplot(3,2,6);
handles=bar(ratiolevels,labelratiohist);
set(handles,'FaceColor','k','EdgeColor','none','BarWidth',1.0);
line([labelratiomean labelratiomean],ylim,'color','r');

set(axes(),'Visible','off')
set(title(titlestr),'visible','on')
_______________________________________________________________________
%% Scatter plot
myinputfiles=1:4;
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titlestr=['Inputfiles
'
num2str(myinputfiles(end))];
xfield='blue';
yfield='green';
titlestr=['Inputfiles
'
num2str(myinputfiles(end)) ...
': ' yfield ' vs. ' xfield];

num2str(myinputfiles(1))

'-'

num2str(myinputfiles(1))

'-'

xvalues=[];
yvalues=[];
for(theinputfile=myinputfiles)
validlabels=inputfile(theinputfile).validlabels;
xvalues=[xvalues
[inputfile(theinputfile).label(validlabels).(xfield)]];
yvalues=[yvalues
[inputfile(theinputfile).label(validlabels).(yfield)]];
end
figure(7);clf
plot(xvalues,yvalues,'bx');
% ylim([0 max(ylim)])
ylim([0 255])
% xlim([0 max(xlim)])
xlim([0 255])
title(titlestr);
_______________________________________________________________________
%% Scatter plot -- overlay
myinputfiles=1:4;
titlestr=['Inputfiles
'
num2str(myinputfiles(end))];
xfield='area';
yfield='greenhi';
titlestr=['Inputfiles
'
num2str(myinputfiles(end)) ...
': ' yfield ' vs. ' xfield];

num2str(myinputfiles(1))

'-'

num2str(myinputfiles(1))

'-'

xvalues=[];
yvalues=[];
for(theinputfile=myinputfiles)
validlabels=inputfile(theinputfile).validlabels;
xvalues=[xvalues
[inputfile(theinputfile).label(validlabels).(xfield)]];
yvalues=[yvalues
[inputfile(theinputfile).label(validlabels).(yfield)]];
end
figure(7);
hold on
plot(xvalues,yvalues,'ro');
% ylim([0 max(ylim)])
% ylim([0 255])
% xlim([0 max(xlim)])
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% xlim([0 20000])
title(titlestr);

_______________________________________________________________________
%% output settings data
if(exist('outfile','var'))
if(~exist(outdir,'dir'))
mkdir(outdir);
end
if(~isempty(roix))
imwrite(myroi,[outdir
'_roimask.tif'],'tif','compression','none');
end
%
% save current channel and merged IMAGES
%
imwrite(red,[outdir
'_red.tif'],'tif','Compression','none');
%
imwrite(green,[outdir
'_green.tif'],'tif','Compression','none');
%
imwrite(blue,[outdir
'_blue.tif'],'tif','Compression','none');
%
imwrite(merged,[outdir
'_merged.tif'],'tif','Compression','none');
%
%
% save current channel and merged FIGURES
%
saveas(1,[outdir outfile '_merged.emf'],'emf');
%
saveas(2,[outdir outfile '_red.emf'],'emf');
%
saveas(3,[outdir outfile '_green.emf'],'emf');
%
saveas(4,[outdir outfile '_blue.emf'],'emf');

%

outfile

outfile
outfile
outfile
outfile

% figure of collected statistics (fig 6)
saveas(6,[outdir outfileloc '_levels.emf'],'emf');

% spit out a log file containing parameters
logfile=fopen([outdir outfile '_log.txt'],'w');
fprintf(logfile,'Input dir: %s \r\n',indir);
fprintf(logfile,'Red squelch: %d \r\n',red_squelch);
fprintf(logfile,'Red limit: %d \r\n',red_limit);
fprintf(logfile,'Green squelch: %d \r\n',green_squelch);
fprintf(logfile,'Green limit: %d \r\n',green_limit);
fprintf(logfile,'Blue squelch: %d \r\n',green_squelch);
fprintf(logfile,'Blue limit: %d \r\n',green_limit);
if(length(h)>1)
fprintf(logfile,'Blur radius: %f \r\n',blur_radius);
end
if(exist('ff_redfile','var'))
fprintf(logfile,'Red correction file: %s \r\n',ff_redfile);
end
if(exist('ff_greenfile','var'))
fprintf(logfile,'Green correction file: %s \r\n',ff_greenfile);
end
fprintf(logfile,'labelstyle: %s \r\n',labelstyle);
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if(~isempty(roix))
fprintf(logfile,'ROI: enabled \r\n');
else
fprintf(logfile,'ROI: none selected \r\n');
end
fclose(logfile);
clear logfile
end
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APPENDIX B:
EDMAN DEGREDATION SEQUENCING
The following figures are the Edman Degredation chromatograms received from
Tufts University. Michael Berne, the director of the Core Facility, evaluated the
sequences of the 5 new SLs (Table B.1).
Table B.1 SL10-14 sequences, selectivity and the analyte it was screed against.
SL

Sequence

Screened Against

Selectivity

SINGLE ANALYTE SCREEN
SL10

R-L-D*-A-R-S-D*-G-B-B-R-M

F PC3

SL13

R-T-D*-G-L-A-D*-V-B-B-R-M

F RWPE-1

SL14

R-Y-D*-R-A-S-D*-V-B-B-R-M

R PC3

DUAL ANALYTE SCREEN
SL11

R-L-D*-Y-L-T-D*-R-B-B-R-M

F RWPE-1/R PC3

PC3

SL12

R-L-D*-G-F-Y-D*-Q-B-B-R-M

F RWPE-1/R PC3

RWPE-1
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77
Figure 5.1 SL10 AA 8. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. R is a fixed position in the SL library.

78
Figure 5.2: SL10 AA 7. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. L is a random position in the SL library.

79
Figure 5.3: SL10 AA 6. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. D* is a fixed position in the library and is not
recognized by Edman Degradation. The fixed position of this AA identifies where it falls in the SL sequence. It is also important to
note that while L does show in the cycle of the sequence, the amount decreases from the cycle before.

80
Figure 5.4: SL10 AA 5. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. A is a random position in the library.

81
Figure 5.5: SL10 AA 4. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. R is a random position in the library.

82
Figure 5.6: SL10 AA 3. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. S is a random position in the library.

83
Figure 5.7: SL10 AA 2. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. D* is a fixed position in the library. The fixed
position of this AA identifies where it falls in the SL sequence.
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Figure 5.8: SL10 AA 1. The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. G is a random position in the library.

85
Figure 5.9: SL11 AA 8. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. R is a fixed position in library.

86
Figure 5.10: SL11 AA 7. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. L is a random position in library.

87
Figure 5.11: SL11 AA 6. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. D* is a fixed position in library.

88
Figure 5.12: SL11 AA 5. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. Y is a random position in library.

89
Figure 5.13: SL11 AA 4. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. L is a random position in library.

90
Figure 5.14: SL11 AA 3. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. T is a random position in library.

91
Figure 5.15: SL11 AA 2. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. D* is a random position in library.

92
Figure 5.16: SL11 AA 1. The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. R is a random position in library.

93
Figure 5.17: SL12 AA 8. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. R is a fixed position in library.

94
Figure 5.18: SL12 AA 7. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. L is a random position in library.

95
Figure 5.19: SL12 AA 6. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. D* is a fixed position in library.

96
Figure 5.20: SL12 AA 5. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. G is a random position in library.

97
Figure 5.21: SL12 AA 4. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. F is a random position in library.

98
Figure 5.22: SL12 AA 3. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. Y is a random position in library.

99
Figure 5.23: SL12 AA 2. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. D* is a fixed position in library.
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Figure 5.24: SL12 AA 1. The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. Q is a random position in library.

101
Figure 5.25: SL13 AA 8. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. R is a fixed position in library.

102
Figure 5.26: SL13 AA 7. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. T is a random position in library.

103
Figure 5.27: SL13 AA 6. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. D* is a fixed position in library.

104
Figure 5.28: SL13 AA 5. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. G is a random position in library.

105
Figure 5.29: SL13 AA 4. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. L is a random position in library.

106
Figure 5.30: SL13 AA 3. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. A is a random position in library.

107
Figure 5.31: SL13 AA 2. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. D* is a fixed position in library.

108
Figure 5.32: SL13 AA 1. The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. V is a random position in library.

109
Figure 5.33: SL14 AA 8. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. R is a fixed position in library.

110
Figure 5.34: SL14 AA 7. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. Y is a random position in library.

111
Figure 5.35: SL14 AA 6. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. D* is a fixed position in library.

112
Figure 5.36: SL14 AA 5. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. R is a random position in library.

113
Figure 5.37: SL14 AA 4. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. A is a random position in library.

114
Figure 5.38: SL14 AA 3. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. S is a random position in library.

115
Figure 5.39: SL14 AA 2. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. D* is a fixed position in library.

116
Figure 5.40: SL14 AA 1. The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. V is a random position in library.

